SEC Form 4 · accession 0001562180-18-002844
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Diane Stroehmann
Officer — See Remarks
Period of report
Jun 1, 2018
Accepted (ET)
Jun 4, 2018 · 9:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 126,686 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F2 | $15.08 | Jun 1, 2018 | A | 48,720 | A | — | Jun 1, 2028 | Common Stock | 48,720 | 48,720 | D |
Explanation of responses
- F1Includes 1,962 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2018.
- F2Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.